Clinical Impact of Genomic Profiling in Lung Cancer Through Real World Cases

This segment shifts the discussion from theory to real world clinical application by focusing on how genomic profiling directly changes treatment decisions in lung cancer. Dr Husain invites Dr Singhal to describe specific patient cases where comprehensive molecular testing altered the initial management plan. Through these examples, the panel illustrates how identifying a driver mutation or actionable alteration can redirect therapy away from standard chemotherapy or immunotherapy and toward a targeted approach that is more effective and often better tolerated.

The experts describe how early detection of mutations such as EGFR, ALK, or rare fusions enables clinicians to offer therapies that are precisely matched to the biology of the tumor. In several cases, genomic testing helped clarify ambiguous clinical situations, such as when imaging and pathology alone could not predict which treatment would provide the greatest benefit. The panel emphasizes that these successes depend on performing broad testing early rather than relying on stepwise or limited panels that may miss important findings.

They also discuss how molecular results can influence patient counseling, allowing clinicians to explain prognosis and treatment options with greater confidence. Patients often feel reassured when therapy is guided by specific features of their cancer rather than by trial and error. This segment reinforces that in modern lung cancer care, genomic profiling is not just a diagnostic add on but a central driver of personalized treatment planning and improved outcomes.